Chimerix, Inc. (NASDAQ:CMRX) Q4 2023 Earnings Conference Call February 29, 2024 8:30 AM ET

Company Participants

Will O'Connor - Stern IR

Mike Andriole - President and CEO

Tom Riga - COO and CCO

Michelle LaSpaluto - CFO

Allen Melemed - CMO

Josh Allen - CTO

Conference Call Participants

Maurice Raycroft - Jefferies

Ed White - H.C. Wainwright

Soumit Roy - Jones Research

Operator

Good morning, ladies and gentlemen, and welcome to the Chimerix Fourth Quarter and Year End 2023 Earnings Conference Call.

I would now like to introduce you to your host for today's call, Will O'Connor of Stern Investor Relations. Please proceed.

Will O'Connor

Thank you, operator. Good morning, everyone, and welcome to the Chimerix fourth quarter and year end 2023 financial and operating results conference call. This morning, we issued a press release related to our fourth quarter operating update. You can access the press release in our Investors section of the website.

With me on today's call are President and Chief Executive Officer, Mike Andriole; Chief Operating and Commercial Officer, Tom Riga, Chief Financial Officer, Michelle LaSpaluto; Chief Medical Officer, Allen Melemed; and Chief Technology Officer, Josh Allen.

Before we begin, I'd like to remind you that the statements made on today's call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties and other factors. These risks and uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. Please refer to our filings with the SEC for a more complete disclosure of these risks and uncertainties.

At this time, I'll now turn the call over to Chimerix President and Chief Executive Officer, Mike Andriole.

Mike Andriole

Thanks, Will, and good morning, everyone, and thank you for joining us.

We're excited to be with you this morning to share the considerable corporate and clinical progress made throughout 2023, highlighted by key management appointments and meaningful advancements across our microtome pipeline. During the fourth quarter, we welcomed Dr. Lisa Decker to our Board of Directors. Dr. Decker brings 25 years of drug development, strategic partnership and corporate transaction experience to our Board.

We also continue to strengthen our management team with the additions of Tom Riga as Chief Operating and Commercial Officer; Michelle LaSpaluto as Chief Financial Officer; and Dr. Pablo Lee as Vice President of Medical Affairs. They have collectively made a strong and immediate impact on the organization, and I'm confident their collective expertise will be invaluable as we seek to maximize our future growth potential for both patients and shareholders.